A Phase 2 interventional study of granisetron in Postoperative Nausea and Vomiting, sponsored by Milton S. Hershey Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2019-12-18.
Sponsored by Milton S. Hershey Medical Center · Phase 2, Interventional, and Treatment
The objective of the study is to evaluate the efficacy and safety of adding transdermal preparation of granisetron (Sancuso ®) to the current postoperative nausea and vomiting (PONV) standard prophylaxis regimen with dexamethasone and ondansetron in patients with the previous history of severe, particularly delayed and/or post-discharge, PONV and undergoing surgical procedure under general anesthesia.
The specific aims of the study include:
Patients will be recruited from the surgical population undergoing preoperative evaluation in Anesthesiology Preoperative Evaluation Clinic at Hershey Med. Ctr. (\~15,000 per year). Selected patients (ASA 1-3, N=60) with history of severe PONV after one or more of previous general anesthesia, and scheduled to undergo surgical procedures with general anesthesia will be enrolled into IRB approved protocol. The patch will be placed by the patient at home 24 - 48 hours before surgery as directed by the doctor. The subsequent standardized general anesthesia protocol for elective surgery will include general endotracheal anesthesia with sevofluran, including standard intraoperative PONV prophylaxis (IV dexamethasone and IV ondansetron, each 4 mg). Postoperative evaluation will include recording of incidence and severity of PONV at the time of discharge from PACU (acute PONV), at 24 hr, 48 hrs, 72 and 120 hrs (delayed or post discharge PONV).
7.2.1 Visit 1 - Anesthesia Preoperative Evaluation Clinic and recruitment and drug dispensation Patient is seen in clinic and identified as having a history of serious PONV, in particular delayed or post discharge PONV. Study will be explained to the patient and consent obtained. The investigational pharmacy will be notified that a study patient has been enrolled and they will prepare the patches for distribution to the patient.
A member of the research team will obtain the assigned patches from the investigational pharmacy and deliver to the anesthesia provider (member of the research team).
The provider will then demonstrate to the patient how to apply the patch and the patient can practice using a placebo patch to show that the correct placement. Patient will then take the actual patch home with them.
7.2.2 Visit 2 - approximately 24-48 hours preoperatively (patient's home) Patient will apply the patch to their upper arm 24-48 hours before scheduled surgical procedure, as instructed during their pre-op anesthesia visit. The patch will then remain in place until 120 hours after surgical procedure. No backup patch will be provided so the patients with the accidently missing patch will need to call their primary surgical service for the standard antiemetic medication.
7.2.3 Visit 3- Day of Surgery Patient will arrive for surgery. A member of the research team will meet them in the SDU and record the time that the patch was applied, and if it has been placed correctly, intact and still in place. Any potential side effects (systemic or local) will be recorded at that time. The subsequent standardized general anesthesia protocol for elective surgery will include general endotracheal anesthesia with sevofluran (no nitrous oxide), muscle relaxants (with reversal), intraoperative IV opioid analgesics, including standard PONV prophylaxis (dexamethasone and ondansetron IV 4 mg).
Early postoperative evaluation will include recording of incidence and severity of PONV at the time of discharge from PACU (acute PONV). The incidence of vomiting or retching will recorded by the nursing staff. Patients with symptoms requiring a rescue antiemetic-nausea score ≥4 on an 11-point Numeric Rating Scale (NRS), retching or vomiting, or patient request-within 6 hours of PACU admission will be given the rescue medication (Benadryl or promethazine). The NRS was an 11-point linear scale on which patients rated their nausea, with 0 meaning no nausea and 10 meaning the worst possible nausea.
The subsequent evaluations will be performed either at the patient's bed (if in the hospital) or by phone call at 24 hr, 48 hrs, 72 and 120 hrs (delayed or post discharge PONV). The patient will be supplied with a diary to record the information that will be requested on the follow-up phone calls.
The primary efficacy endpoint will be complete response (CR), defined as no emetic episode and no rescue medication; the proportions of patients with no emesis and no additional rescue medication in the 120 hours following the completion of surgical procedure and the change from baseline nausea score using the NRS. Treatment-emergent adverse events (TEAEs), regardless of suspected causal relationship to the study medication, will be also recorded throughout and continued until 5 days after surgery.
7.3 Duration of Participation Patient will remain in the study until all time points have been met (maximum 5 days following surgery or 120 hours). At the end of the study the patient will remove and dispose the remaining patch.
822 studies on the registry are indexed under Nausea; 104 are open to participants now.
This study's enrollment of 50 is below the median of 115 across 703 interventional studies indexed under Nausea.
Browse Nausea studies →Milton S. Hershey Medical Center is the lead sponsor of 480 studies on the registry; 61 are open to participants now.
Of its 56 completed or terminated interventional studies of FDA-regulated products, 42 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Preoperative administration of granisetron transdemal patch
Drug: granisetron
Application granisetron transdermal patch preoperatively
Also known as: Sancuso
Number of Participants With Complete Response (CR), No PONV Symptoms, Nausea
Composite measure consisting of complete response (CR), defined as no emetic episode and no rescue medication; the proportions of patients with no emesis and no additional rescue medication in the 120 hours following the completion of surgical procedure.
Time frame: 24 hrs, 48 hrs, 72 hrs and 120 hrs
| Milestone | Admnistration of Granisetron |
|---|---|
| Started | 50 |
| Completed | 41 |
| Not completed | 9 |
| Withdrew: Adverse event | 3 |
| Withdrew: Protocol violation | 2 |
| Withdrew: Withdrawal by subject | 4 |
Composite measure consisting of complete response (CR), defined as no emetic episode and no rescue medication; the proportions of patients with no emesis and no additional rescue medication in the 120 hours following the completion of surgical procedure.
| Participants | Admnistration of Granisetron |
|---|---|
| Completed Response : 24 hrs | 8 |
| Completed Response : 48 hrs | 25 |
| Completed Response : 72 hrs | 24 |
| Completed Response : 120 hrs | 28 |
| No PONV symptoms : 24 hrs | 18 |
| No PONV symptoms : 48 hrs | 25 |
| No PONV symptoms : 72 hrs | 24 |
| No PONV symptoms : 120 hrs | 28 |
| Nausea : 24 hrs | 21 |
| Nausea : 48 hrs | 11 |
| Nausea : 72 hrs | 7 |
| Nausea : 120 hrs | 3 |
| Vomiting with or without retching : 24 hrs | 5 |
| Vomiting with or without retching : 48 hrs | 2 |
| Vomiting with or without retching : 72 hrs | 0 |
| Vomiting with or without retching : 120 hrs | 0 |
| Retching (dry-hives, without vomiting) : 24 hrs | 3 |
| Retching (dry-hives, without vomiting) : 48 hrs | 1 |
| Retching (dry-hives, without vomiting) : 72 hrs | 0 |
| Retching (dry-hives, without vomiting) : 120 hrs | 0 |
Collected over 120 hours. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Admnistration of Granisetron | 0/50 (0%) | 0/50 (0%) | 13/50 (26%) |
| Event | Admnistration of Granisetron |
|---|---|
| skin irritationSkin and subcutaneous tissue disorders | 6/50 |
| constipationGastrointestinal disorders | 2/50 |
| diarrheaGastrointestinal disorders | 1/50 |
| hallucinationNervous system disorders | 1/50 |
| dizzinessGeneral disorders | 1/50 |
| headacheGeneral disorders | 1/50 |
| EKG changesCardiac disorders | 1/50 |
| Age, Customized(participants) | Admnistration of Granisetron |
|---|---|
| 18-21 years : female | 0 |
| 18-21 years : male | 0 |
| 22-29 years : female | 2 |
| 22-29 years : male | 0 |
| 30-39 years : female | 5 |
| 30-39 years : male | 0 |
| 40-49 years : female | 13 |
| 40-49 years : male | 0 |
| 50-59 years : female | 11 |
| 50-59 years : male | 2 |
| 60-69 years : female | 13 |
| 60-69 years : male | 0 |
| 70-79 years : female | 3 |
| 70-79 years : male | 0 |
| 80-89 years : female | 1 |
| 80-89 years : male | 0 |
| Sex: Female, Male(Participants) | Admnistration of Granisetron |
|---|---|
| Female | 48 |
| Male | 2 |
| Ethnicity (NIH/OMB)(Participants) | Admnistration of Granisetron |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 49 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Admnistration of Granisetron |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 47 |
| More than one race | 1 |
| Unknown or Not Reported | 1 |
| Baseline Participants who completed study(Participants) | Admnistration of Granisetron |
|---|---|
| 18-21 years : female | 0 |
| 18-21 years : male | 0 |
| 22-29 years : female | 2 |
| 22-29 years : male | 0 |
| 30-39 years : female | 5 |
| 30-39 years : male | 0 |
| 40-49 years : female | 13 |
| 40-49 years : male | 0 |
| 50-59 years : female | 5 |
| 50-59 years : male | 2 |
| 60-69 years : female | 11 |
| 60-69 years : male | 0 |
| 70-79 years : female | 2 |
| 70-79 years : male | 0 |
| 80-89 years : female | 1 |
| 80-89 years : male | 0 |
Documents are hosted by the registry — open the source record to download them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Milton S. Hershey Medical Center